The drug-device combination market is expected to grow by 9.9 percent to $30.5 billion by 2017, said a report from BCC Research, according to Healthcare Packaging. The market was valued at $18.5 billion in 2011 and reached $19 billion in 2012.
The report also estimates 30 percent of all healthcare products currently under develop are combination devices with built-in pharmaceutical or biologic components.
Combination devices include orthopedic applications, coronary stents, photodynamic therapies and antimicrobial catheters.
More Articles on Devices:
Alphatec Spine Receives FDA Clearance for 2 Cervical, Fixation Devices
Zimmer Recall Labeled High Risk by FDA
Orthopedic Device Company DJO Global Acquires Exos Corp
The report also estimates 30 percent of all healthcare products currently under develop are combination devices with built-in pharmaceutical or biologic components.
Combination devices include orthopedic applications, coronary stents, photodynamic therapies and antimicrobial catheters.
More Articles on Devices:
Alphatec Spine Receives FDA Clearance for 2 Cervical, Fixation Devices
Zimmer Recall Labeled High Risk by FDA
Orthopedic Device Company DJO Global Acquires Exos Corp